The stock of GenMark Diagnostics, Inc (NASDAQ:GNMK) is a huge mover today! The stock increased 8.46% or $0.92 during the last trading session, hitting $11.8. About 429,865 shares traded hands. GenMark Diagnostics, Inc (NASDAQ:GNMK) has risen 120.24% since February 26, 2016 and is uptrending. It has outperformed by 109.82% the S&P500.
The move comes after 6 months positive chart setup for the $472.18 million company. It was reported on Sep, 30 by Barchart.com. We have $30.56 PT which if reached, will make NASDAQ:GNMK worth $750.77M more.
Analysts await GenMark Diagnostics, Inc (NASDAQ:GNMK) to report earnings on October, 25. They expect $-0.31 earnings per share, down 14.81% or $0.04 from last year’s $-0.27 per share. After $-0.30 actual earnings per share reported by GenMark Diagnostics, Inc for the previous quarter, Wall Street now forecasts 3.33% negative EPS growth.
GenMark Diagnostics, Inc (NASDAQ:GNMK) Ratings Coverage
Out of 3 analysts covering Genmark Diagnostics (NASDAQ:GNMK), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Genmark Diagnostics has been the topic of 5 analyst reports since October 14, 2015 according to StockzIntelligence Inc. Needham maintained the stock with “Buy” rating in Wednesday, February 24 report. The rating was upgraded by Cowen & Co to “Outperform” on Friday, September 16. The firm earned “Buy” rating on Wednesday, October 28 by Needham.
According to Zacks Investment Research, “GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensorÂ® XT-8 system is the second generation in GenMark Dx’s eSensorÂ® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual’s ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual’s increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.”
Insitutional Activity: The institutional sentiment decreased to 0.91 in Q2 2016. Its down 0.50, from 1.41 in 2016Q1. The ratio fall, as 11 funds sold all GenMark Diagnostics, Inc shares owned while 23 reduced positions. 3 funds bought stakes while 28 increased positions. They now own 43.35 million shares or 1.06% less from 43.82 million shares in 2016Q1.
Blackrock Advsrs Ltd Llc has 20,714 shares for 0% of their US portfolio. Donaldson Cap Management has 66,425 shares for 0.08% of their US portfolio. Teachers accumulated 0% or 92,374 shares. Weiss Multi has invested 0.05% of its portfolio in GenMark Diagnostics, Inc (NASDAQ:GNMK). Tci Wealth, a Arizona-based fund reported 7,009 shares. Northern Tru Corp accumulated 0% or 499,387 shares. Mackenzie has 0% invested in the company for 74,800 shares. Blackrock Fund Advsr last reported 1.05M shares in the company. Royal Fincl Bank Of Canada holds 1,356 shares or 0% of its portfolio. Legal General Gp Public Ltd has 0% invested in the company for 8,127 shares. Moreover, National Bank Of America De has 0% invested in GenMark Diagnostics, Inc (NASDAQ:GNMK) for 4,430 shares. Cadian Management L P accumulated 4.08M shares or 1.95% of the stock. Adage Cap Prtn Group Inc Limited Com owns 2.70M shares or 0.06% of their US portfolio. California State Teachers Retirement reported 84,174 shares or 0% of all its holdings. Geode Cap Limited Liability Corp accumulated 311,076 shares or 0% of the stock.
Insider Transactions: Since May 9, 2016, the stock had 1 insider buy, and 24 selling transactions for $416,178 net activity. Another trade for 310 shares valued at $2,672 was sold by Stier Eric. On Wednesday, September 7 Kayyem Jon Faiz sold $2,694 worth of the stock or 310 shares. The insider Williams Jennifer Anne sold $51,627. On Friday, September 2 Gleeson Michael sold $3,086 worth of the stock or 358 shares. 184 shares with value of $1,570 were sold by Chakravarty Ingo on Friday, June 3. Shares for $11,332 were sold by MASSARANY HANY on Tuesday, August 2. On Friday, August 12 Giles Lisa M. bought $7,736 worth of the stock or 823 shares.
More recent GenMark Diagnostics, Inc (NASDAQ:GNMK) news were published by: Fool.com which released: “Why GenMark Diagnostics, Inc. Is Soaring Today” on September 16, 2016. Also Quotes.Wsj.com published the news titled: “News GenMark Diagnostics Inc.GNMK” on February 11, 2011. Finance.Yahoo.com‘s news article titled: “Can the Rally in GenMark Diagnostics (GNMK) Shares Continue?” with publication date: September 21, 2016 was also an interesting one.
GNMK Company Profile
GenMark Diagnostics, Inc. (GenMark), incorporated on February 12, 2010, is a molecular diagnostics company. The Firm focuses on developing and commercializing its eSensor detection technology. The Company’s eSensor electrochemical technology enables detection of multiple distinct biomarkers in a single sample. The Firm sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. In addition, it has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. The Company’s XT-8 system received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular research and diagnostic tests with a workstation and disposable test cartridges. The Company’s XT-8 system supports approximately 20 independent test cartridges. It has an installed base of over 630 XT-8 analyzers, or placements, with its customers. It has a menu of approximately eight tests for use with its XT-8 system. Approximately four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.